Nuclear GSK3β Promotes Tumorigenesis by Phosphorylating KDM1A and Inducing Its Deubiquitylation by USP22

Aidong Zhou,Kangyu Lin,Sicong Zhang,Yaohui Chen,Nu Zhang,Jianfei Xue,Zhongyong Wang,Kenneth D. Aldape,Keping Xie,James R. Woodgett,Suyun Huang

DOI: https://doi.org/10.1038/ncb3396

IF: 21.3

2016-01-01

Nature Cell Biology

Abstract:Emerging evidence has shown that GSK3β plays oncogenic roles in multiple tumour types; however, the underlying mechanisms remain largely unknown. Here, we show that nuclear GSK3β is responsible for the accumulation of the histone demethylase KDM1A and critically regulates histone H3K4 methylation during tumorigenesis. GSK3β phosphorylates KDM1A Ser683 upon priming phosphorylation of KDM1A Ser687 by CK1α. Phosphorylation of KDM1A induces its binding with and deubiquitylation by USP22, leading to KDM1A stabilization. GSK3β- and USP22-dependent KDM1A stabilization is required for the demethylation of histone H3K4, thereby repressing BMP2, CDKN1A and GATA6 transcription, which results in cancer stem cell self-renewal and glioblastoma tumorigenesis. In human glioblastoma specimens, KDM1A levels are correlated with nuclear GSK3β and USP22 levels. Furthermore, a GSK3 inhibitor, tideglusib, sensitizes tumour xenografts to chemotherapy in mice via KDM1A downregulation and improves survival. Our findings demonstrate that nuclear GSK3β- and USP22-mediated KDM1A stabilization is essential for glioblastoma tumorigenesis. Zhou et al. show that GSK3β phosphorylates KDM1A and induces its deubiquitylation by USP22, leading to demethylation of histone H3K4 and glioblastoma progression.